Clal Insurance’s AstraZeneca AZN Stock Holding History

Clal Insurance’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38K	Sell	206 -52	-20%	-$9.78K	﹤0.01%	140
2026 Q1	$50K	Buy	258 +173	+204%	+$33.4K	﹤0.01%	128
2025 Q4	$16K	Sell	85 -20	-19%	-$3.51K	﹤0.01%	168
2025 Q3	$16K	Sell	105 -10	-9%	-$1.51K	﹤0.01%	177
2025 Q2	$16K	Sell	115 -4	-3%	-$561	﹤0.01%	169
2025 Q1	$17K	Buy	119 +96	+417%	+$13.9K	﹤0.01%	167
2024 Q4	$3K	Sell	23 -1,477	-98%	-$207K	﹤0.01%	159
2024 Q3	$234K	Buy	+1,500	New	+$242K	﹤0.01%	110
2023 Q3	–	Sell	-220,000	Closed	-$31.5M	–	137
2023 Q2	$31.5M	Hold	220,000	–	–	0.38%	61
2023 Q1	$30.5M	Sell	220,000 -5,000	-2%	-$673K	0.46%	61
2022 Q4	$30.5M	Hold	225,000	–	–	0.46%	58
2022 Q3	$24.7M	Buy	225,000 +1,500	+0.7%	+$190K	0.34%	68
2022 Q2	$29.5M	Buy	+223,500	New	+$29.3M	0.39%	62

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Clal Insurance's AZN Position: Q2 2026 in Review

Clal Insurance reduced its AstraZeneca (AZN) stake by 20% in Q2 2026, selling an estimated $9.78K and leaving 206 shares worth $38K. The position accounts for ﹤0.01% of the portfolio, ranked #140.

Clal Insurance first reported a position in AZN in Q2 2022 and has held it in 13 quarters since. The position peaked at $31.5M in Q2 2023. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Clal Insurance held 206 shares of AstraZeneca worth $38K as of Q2 2026.
Clal Insurance sold 52 AstraZeneca shares in Q2 2026, an estimated $9.78K.
AstraZeneca made up ﹤0.01% of Clal Insurance's portfolio in Q2 2026, its #140 holding.
Clal Insurance first reported a position in AstraZeneca in Q2 2022 and has held it in 13 quarters since.
Clal Insurance's AstraZeneca position peaked at $31.5M in Q2 2023.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Clal Insurance's 13F filing for Q2 2026, filed 13 Aug 2026.